Orphan drug status for Gaucher disease drug (About.com)
In February 2006 the U.S. Food and Drug Administration (FDA) approved orphan drug status for AT2101 (Amicus Therapeutics, Inc.) for the treatment of Gaucher disease, a lysosomal storage disorder resulting from deficiency of the enzyme glucocerebrosidase. AT2101 is an oral...